Company intelligence / Profile preview

NexStep Medical

Dijon, Bourgogne Franche Comté, Francenexstepmedical.com ↗
Ownership
Private
Development stage
Commercial
01

Overview

NexStep Medical has successfully completed first-in-human use of its All’InCath 035M product for percutaneous transluminal angioplasty. Physician feedback confirms reduced procedural time and contrast media usage during routine PTA procedures.

Therapeutic areas
Cardiovascular
Modalities
DeviceEndovascular/angioplasty catheter
Industry
Surgical Medical Devices
02

Drug pipeline

1 asset

All'InCath 035M

Commercial
Indications
Peripheral vascular disease, Arteriovenous fistula stenosis
03

Partnerships

Not publicly disclosed as of June 2025

Beyond the preview

Go deeper on NexStep Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Full profile access

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Full profile access

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Full profile access

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Full profile access

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Full profile access

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on NexStep Medical.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call